28 min
Season 2| China: Shawn Xiang on Building China's Rare Disease Ecosystem Behind Biotech
-
- Entrepreneurship
Shawn Xiang Biography
Dr. Xiang is the CEO of Rarestone Group, a company building the first rare disease ecosystem in China. Dr. Xiang has more than 15 years of leadership experience in pharmaceutical and medical device industries. Prior to RareStone, Shawn was the General Manager of Greater China and Emerging Asia Region at Abbott Diabetes Care, where he led his team and successfully launched FreeStyle Libre in China, Korea and Southeast Asia markets and achieved hyper-growth consecutively over the years. Shawn also led his team to build an ecosystem for patients living with Type 1 Diabetes, through strong collaboration with patient organizations, governments and industry partners. Prior to Abbott, Shawn served as the Franchise Head of Bone Disease and Respiratory Disease at Novartis China. He also served as the Director of Global Pharma Strategy at Novartis Global in Switzerland. Earlier in his career, Shawn was an Engagement Manager at McKinsey & Co. in the USA. Dr. Xiang holds a PhD degree from Yale University and a BS degree from Peking University.
On this episode of Behind Biotech, we discussed with Shawn:
Common misconceptions about rare disease in China
Recent catalysts which catapulted rare disease development in China
Rarestone’s unique model which combines a traditional biotech with a digital patient ecosystem
Shawn Xiang Biography
Dr. Xiang is the CEO of Rarestone Group, a company building the first rare disease ecosystem in China. Dr. Xiang has more than 15 years of leadership experience in pharmaceutical and medical device industries. Prior to RareStone, Shawn was the General Manager of Greater China and Emerging Asia Region at Abbott Diabetes Care, where he led his team and successfully launched FreeStyle Libre in China, Korea and Southeast Asia markets and achieved hyper-growth consecutively over the years. Shawn also led his team to build an ecosystem for patients living with Type 1 Diabetes, through strong collaboration with patient organizations, governments and industry partners. Prior to Abbott, Shawn served as the Franchise Head of Bone Disease and Respiratory Disease at Novartis China. He also served as the Director of Global Pharma Strategy at Novartis Global in Switzerland. Earlier in his career, Shawn was an Engagement Manager at McKinsey & Co. in the USA. Dr. Xiang holds a PhD degree from Yale University and a BS degree from Peking University.
On this episode of Behind Biotech, we discussed with Shawn:
Common misconceptions about rare disease in China
Recent catalysts which catapulted rare disease development in China
Rarestone’s unique model which combines a traditional biotech with a digital patient ecosystem
28 min